Editas Medicine’s $231 Million Stock Offering

Davis Polk advised the underwriters in the offering.

Editas Medicine, Inc. executed its $231 million common stock offering of 3,500,000 shares of common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “EDIT.”

Based in Cambridge, Massachusetts, Editas Medicine is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases.

The Davis Polk corporate team advising J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters, included partner Richard D. Truesdell Jr. (Picture), counsel Katia Brener and associates Dennis Chu and Adam Greene. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and Hilary Smith.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Katia Brener – Davis Polk & Wardwell; Dennis Chu – Davis Polk & Wardwell; Adam Greene – Davis Polk & Wardwell; Hilary Smith – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: J.P. Morgan Securities LLC; Morgan Stanley;


Author: Ambrogio Visconti